Leads Biolabs Receives Orphan Drug Designation from the US FDA for LBL-034, a Uniquely Designed, Highly Differentiated Anti-GPRC5D/CD3 Bispecific Antibody, for the Treatment of Multiple Myeloma
NANJING, China, Nov. 6, 2024 /PRNewswire/ — On November 1, Nanjing Leads…